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AbstrAct:
Epithelial mesenchymal transition (EMT) is proposed as a critical mechanism for 
the acquisition of malignant phenotypes by epithelial cells. In colorectal cancer, 
tumor cells having undergone EMT are histologically represented by the presence 
of tumor buds defined as single cells or small clusters of de-differentiated tumor 
cells at the invasive front. Tumor budding is not a static, histological feature rather 
it represents a snap-shot of a dynamic process undertaken by an aggressive tumor 
with the potential to disseminate and metastasize. Strong, consistent evidence 
shows that tumor budding is a predictor of lymph node metastasis, distant 
metastatic disease, local recurrence, worse overall and disease-free survival time 
and an independent prognostic factor. Moreover, the International Union against 
Cancer (UICC) recognizes tumor budding as a highly relevant, additional prognostic 
parameter. The aim of this review is to summarize the evidence supporting the 
implementation of tumor budding into diagnostic pathology and patient management 
and additionally to illustrate its worthiness as a potential therapeutic target.
INtrODUctION
Epithelial mesenchymal transition (EMT) is 
proposed as a critical mechanism for the acquisition 
of malignant phenotypes by epithelial cells [1]. In 
colorectal cancer, tumor cells having undergone EMT 
are histologically represented by the presence of tumor 
buds  defined  as  single  cells  or  small  clusters  of  de-
differentiated tumor cells at the invasive front [2]. 
Tumor budding is predictive of lymph node metastasis, 
vascular and lymphatic invasion, distant metastasis, local 
recurrence  and  poor  disease-specific  survival  time  [3-
15]  and  classified  as  an  “additional”  prognostic  factor 
by the International Union against Cancer (UICC) [16]. 
Despite these highly negative attributes, surprisingly little 
is known about the events promoting a tumor budding 
phenotype although in vitro and xenograft animal models 
of EMT may provide the first clues [17-20]. The aim of 
this review is to summarize the evidence supporting not 
only the integration of tumor budding into daily diagnostic 
pathology and clinical management of colorectal cancer 
patients but also the targeting of tumor budding as a novel 
therapeutic approach for patients with this disease.
EPItHELIAL MEsENcHYMAL 
trANsItION
EMT is a biological process allowing a polarized 
cell, normally interacting with a basement membrane, 
to assume a mesenchymal phenotype characterized by 
increased migratory capacity, invasiveness, increased 
resistance to apoptosis and increased production of 
extracellular matrix (ECM) components [18]. The 
completion of EMT is signaled by the degradation of the 
basement membrane and formation of a mesenchymal cell. 
Highly relevant for embryogenesis and wound healing, 
EMT has also been proposed as a critical mechanism for 
the acquisition of malignant phenotypes by epithelial cells 
[21]. EMT-derived tumor cells occurring at the invasive 
tumor front are thought to be those cells entering into 
subsequent steps of invasion and metastasis. Moreover, 
these cells have been shown to establish secondary 
colonies at distant sites that histopathologically resemble 
the primary tumor of origin through a process known as 
mesenchymal epithelial transition (MET) [21]. Oncotarget 2010; 1:  651 - 661 652 www.impactjournals.com/oncotarget
HIstOPAtHOLOGIcAL AsPEcts OF 
tUMOr bUDDING
In colorectal cancer, EMT-derived tumor cells are 
represented histopathologically by the presence of tumor 
buds  and  are  reported  to  occur  in  20-40%  of  tumours 
[22, 23]. Occurring predominantly at the invasive front, 
the identification of tumor buds, defined as single cells 
or clusters of up to 5 cells can be made using standard 
H&E-stained slides or facilitated by using pan-cytokeratin 
stains  (Figure 1) [2]. In addition, these budding cells 
can  often  be  seen  in  the  company  of  “pseudo-like” 
cytoplasmic protrusions in direct contact with adjacent 
structures which are thought to be a marker of an activated 
budding phenotype associated with cell motility and 
increased  invasiveness  [24].  Histologically,  high-grade 
tumor budding seems to correlate with certain parameters 
[25],  most  notably  with  the  infiltrating  tumor  border 
configuration defined as widespread dissection of normal 
tissue structures with loss of a clear boundary between 
tumor and host tissues [23]. On the other hand, tumor 
budding  occurs  significantly  less  often  in  tumors  with 
a  more  “encapsulating”  or  pushing/expanding  growth 
pattern [26], itself frequently, but not always, accompanied 
by the presence of dense peritumoral lymphocytic (PTL) 
inflammation [27]. 
ActIVAtION OF tHE tUMOr bUDDING 
PHENOtYPE
The study of EMT and its related signaling pathways 
could provide the first clues regarding the molecular and 
genetics events promoting tumor budding in colorectal 
cancers. EMT-inducing signals from the tumor-associated 
stroma such as hepatocyte growth factor (HGF), epidermal 
growth  factor  (EGF),  placental-derived  growth  factor 
(PDGF) and transforming growth factor-beta (TGF-beta) 
appear to be responsible for the induction or functional 
activation  in  cancer  cells  of  a  series  of  EMT-inducing 
transcription factors such as Snail, Slug, ZEB1, Twist, 
Goosecoid and FoxC2 [21, 28-31]. Their implementation 
into the EMT program may depend on a series of 
intracellular signaling networks involving ERK, MAPK, 
PI3K, AKT, the SMADs, and integrins [32-34]. The WNT/
Wingless signaling pathway, and its major effectors beta-
catenin and E-cadherin are however considered integral 
components  of  EMT  [21,  28].  Briefly,  binding  of  wnt 
proteins to a seven-span-transmembrane receptor frizzled 
(frz) leads to activation of WNT signaling and stabilization 
of cytoplasmic beta-catenin which can translocate to the 
cell membrane or nucleus, by mechanisms including 
regulation of cytokines, matrix metalloproteases (MMPs), 
TGF-beta,  tumor  necrosis  factor  (TNF)-alpha  and 
HGF  [35].  Membranous  beta-catenin  complexes  with 
E-cadherin, a critical mediator of cell-cell adhesion and 
responsible for the maintenance of cell polarity [22]. 
In  contrast,  nuclear  beta-catenin  can  function  as  an 
oncogene, binding to Tcf/LEF family members and acting 
as a transcriptional activator of downstream target genes 
[36]. Hence, membranous expression of both beta-catenin 
and  E-cadherin  characterizes  the  epithelial  phenotype, 
whereas loss is indicative of a switch toward a more 
mesenchymal  one.  Up-regulation  of  proteins  involved 
in ECM degradation, angiogenesis and migration such 
as  MMP-7,  MMP-26,  urokinase  plasminogen  activator 
receptor (uPAR), vascular endothelial growth factor 
(VEGF), laminin5γ2 -chain, fibronectin and CD44 [22] 
have all been reported. 
IMMUNOHIstOcHEMIcAL stUDEs 
Immunohistochemical studies have been crucial for 
improving our understanding of tumor budding (Figure 
Figure 1: tumor budding. Single tumor buds (arrow) at the invasive front of colorectal cancer (H&E, 40x) (A). The pan-cytokeratin 
staining better visualizes the number of tumor buds in the same area at the invasive front (CK22, 40x) (B).
A) H&E; 40x B) CK22; 40xOncotarget 2010; 1:  651 - 661 653 www.impactjournals.com/oncotarget
2). High-grade tumor budding is often linked to increased 
expression of protein markers closely related to ECM 
degradation such as uPA and uPAR, matrilysin or MMPs as 
well as those often associated with increased proliferation 
such  as  TGF-beta,  epidermal  growth  factor  receptor 
(EGFR), and p53 [37-43]. Markers of cell adhesion and 
migration such as E-cadherin or syndecan-1 are decreased 
in the center of tumors with high-grade tumor budding in 
addition to decreased phospho-AKT, a protein reported 
to impact cell survival by inhibiting apoptosis [44-46]. 
Decreased EphB2 and Bcl-2 have been documented [47]. 
Interestingly,  the  number  of  CD8+  tumor  infiltrating 
lymphocytes (TILs) is markedly decreased in high-grade 
budders, probably due to the relationship of the immune 
response with microsatellite instability (MSI) status [46]. 
Most interesting is the heterogeneity of expression of 
several markers, predominantly related to cell adhesion, 
from the tumor centre to the tumor front. Loss of 
membranous E-cadherin, CD44, CD44v6, EpCAM and 
CD166 expression have all been reported and often are 
not expressed within tumor budding cells themselves 
[48-51]. The finding of loss of these markers associated 
with  more  aggressive  tumor  behavior  and  high-grade 
tumor budding may be related to the loss of cell adhesion 
function which is represented by membranous staining of 
these markers by immunohistochemistry. Several studies 
have documented the changes in membranous to more 
cytoplasmic  expression  and  dual-functions  of  proteins 
such  as  E-cadherin,  EpCAM  and  CD44  with  tumor 
progression, hence caution should therefore be taken to 
note the intra-cellular localization of these, and possibly 
other cell adhesion molecules [52-54]. 
Tumor buds themselves shows a strong and uniform 
nuclear  beta-catenin  staining  and  concomitant  loss  of 
membranous  E-cadherin  expression,  in  line  with  what 
is seen in EMT studies [21, 55, 56]. In addition, over-
expression  of  ECM  degradation  proteins  MMP-2  and 
MMP-9, uPAR, and laminin5γ2 have all been reported 
[41, 57-59]. Additional studies have related tumor budding 
to increased expression of putative stem cell markers 
Figure 2: Overview of different histological features, molecular factors and protein markers linked to high-grade tumor 
budding. Protein markers have been evaluated in the tumor centre or within tumor budding cells. Additionally, changes in protein expression 
from the tumor centre to the invasive front have also been related to the presence of tumor budding. Expression described predominantly as 
n=nuclear, m=membranous, or c=cytoplasmic. Yellow circles represent lymphocytes, in particular CD8+ T-cells.
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CD133  and ABCG5,  as  well  as  of  beta-III  tubulin,  a 
protein involved in migration, CXCL12, a stromal cell-
derived factor involved in chemotaxis and angiogenesis, 
hMena, a marker of cell motility and cathepsinB linked 
to  dedifferentiation  [57,  60-63].  Interestingly, ABCG5-
expressing  and  non-expressing  buds  have  differential 
effects on patient survival supporting the notion that the 
level of aggressiveness of tumor buds may depend on 
their protein profiles [64]. Despite the clear association of 
tumor budding with migration and invasion, paradoxically, 
tumor buds seem to undergo low rates of proliferation 
as evidenced by reduced expression of proliferation 
marker  Ki67  and  concomitant  increased  expression  of 
cell-cycle arrest mediators cyclin D1 and p16 [65, 66].   
tUMOr bUDDING AND 
MIcrOsAtELLItE INstAbILItY
Whether  of  sporadic  or  hereditary  origin,  tumors 
with high-level MSI (MSI-H; 15% of all cases), seem to 
have very low rates or no tumor budding [67]. In addition, 
in vitro studies comparing microsatellite stable (MSS) and 
MSI-H cell lines confirm the reduced EMT in the latter. 
Several contributing factors may help explain this finding.
Attacker/Defender Model: 
The invasive front of colorectal cancers can be 
thought of as a dynamic interface of pro- and anti-tumor 
factors. On the one hand, tumor buds promote progression 
and dissemination by attempting to penetrate vascular and 
Figure 3: the invasive front of colorectal cancer highlighting the interaction between tumor buds and peritumoral 
inflammatory cells. (H&E, 20x) (A). Double staining with CK22 showing presence of inflammatory cells positive for CD8 (B), FoxP3 (C) 
and CD68 (D) in the microenvironment of tumor buds (40x). Arrows showing examples of tumor buds (solid) and CD8+, FoxP3+ and CD68+ 
cells (dotted), respectively.
A) H&E; 20x B) CK22/CD8; 40x
C) CK22/FoxP3; 40x D) CK22/CD68; 40xOncotarget 2010; 1:  651 - 661 655 www.impactjournals.com/oncotarget
lymphatic vessels. On the other, the host attempts to fend 
off this attack by mounting an immune response composed 
primarily of cytotoxic T lymphocytes, to protect vascular 
and lymphatic channels from invasion by tumor buds [68]. 
MSI-H colorectal cancers exemplify this attacker/defender 
model and highlight a pro-immunogenic phenotype which 
may to some extent be responsible for the more favorable 
prognosis of patients with these forms of colorectal 
cancers  [69].  In  comparison  to  MSS  tumors,  MSI-H 
cancers are known to have abundant CD8+ intra-epithelial 
and stromal TILs [70, 71]. They are most often found 
with pushing tumor borders accompanied by dense PTL 
inflammation [71]. It has been previously hypothesized 
that  specific  immune  responses  contained  within  this 
PTL infiltrate may be targeting tumor budding cells for 
destruction, hence their frequent absence at the invasive 
front  in  tumors  with  strong  lymphocytic  inflammation 
[46]. We recently investigated the composition of the PTL 
infiltrate  in  MSI-H  and  MSS  tumors  within  the  tumor 
budding microenvironment [72]. Several differences were 
found including a greater number of CD8+, granzymeB+, 
CD16+ and CD3+ cells in MSI-H cases. Although the 
presence  of  CD8+  cells  among  patients  with  MSI-H 
tumors  does  not  seem  to  influence  outcome  [73],  the 
ratio between CD8+, FOXp3+ and CD68+ cells and the 
presence of tumor budding has an independent effect on 
prognosis in both MSS and MSI-H cancers (Figure 3). 
Even  in  cases  with  no  obvious  PTL  inflammation,  the 
higher the number of CD8+, FOXp3+ and CD68+ cells 
relative to the number of tumor buds (ratio of immune 
cells-defenders /tumor budding cells-attackers), the more 
favorable  the  impact  on  patient  survival  [72].  MSI-H 
cancers are known to metastasize to a much lesser degree 
than  their  MSS  counterparts;  the  abundant  immune 
reaction at the invasive front and particularly within 
the microenvironment of tumor budding cells may help 
further to explain this observation.
WNT pathway signaling
The  Wnt  signaling  pathway,  as  seen  in  EMT 
studies in vitro, is believed to be highly relevant to tumor 
budding in human colorectal cancer patients. Classically, 
chromosomally instable (CIN) or MSS but not MSI-H 
tumors may arise from inactivation of Wnt signaling [67]. 
Nuclear accumulation of beta-catenin is typically found in 
MSS colorectal cancers, occurs particularly at the invasive 
front and within tumor budding cells, and is simultaneously 
observed in cases with loss of membranous E-cadherin. 
MSI-H colorectal cancers typically do not show mutations 
in neither APC, nor present with tumor buds [67, 74]. 
The frequency of concomitant APC mutation and tumor 
budding stratified by MSI status is illustrated in Figure 
Figure 4: Association between APC mutation and tumor budding stratified by microsatellite instability status (adapted 
from Jass et al. J Clin Pathol, 2003). Sporadic MSI-H colorectal cancers show the lowest rates of both APC mutation and tumor budding 
followed by hereditary MSI-H (Lynch syndrome; Hereditary Non-Polyposis Colorectal Cancer) cases, and low-level MSI tumors. Microsatellite 
stable (MSS) cancers show the greatest rates of tumor budding, accompanied by frequent APC mutation, thus substantiating the relationship 
between Wnt signaling and this histopathological feature.
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4 [67]. The close relationship between the two features 
suggests a strong interaction between inactivation of Wnt 
signaling and the presence of tumor budding.
CpG Island Methylator Phenotype
MSI-H colorectal cancers have now been linked to 
high-level CpG Island Methylator Phenotype (CIMP-H), a 
feature itself strongly related to methylation of CDKN2A 
(p16) [75]. P16INK4A is known to be a target gene of beta-
catenin and often the two proteins are co-expressed within 
tumor budding cells [76]. Methylation of CDKN2A may 
lead to gene silencing and consequently decreased levels 
of nuclear p16INK4a protein expression [77]. It is therefore 
expected  that  tumor  budding  should  be  significantly 
reduced in patients with CIMP-H tumors. Only a handful 
of studies to date have evaluated CDKN2A methylation in 
the context of tumor budding. Prall and colleagues found 
6  cases  of  high-grade  tumor  budding  with  a  complete 
absence of nuclear p16INK4a protein expression (10.5%) 
and all had concomitant p16INK4a methylation [78]. Eleven 
methylated cases retained expression of the protein and 
interestingly, cases with high-grade tumor budding often 
did not stain for nuclear p16INK4a. This lack of concordance 
between methylation and protein expression has been also 
described previously [79] and may possibly be explained 
by  the  intra-cellular  localization  of  p16. Accumulation 
of cytoplasmic, rather than nuclear p16 staining has 
been observed within tumor budding cells [67]. Jass and 
colleagues hypothesized that the cytoplasmic p16 may 
bind cdk4 and block its translocation to the nucleus. In 
the absence of cdk4, cyclinD1 may complex with cdk2 
thus limiting the availability of cyclins A and E and 
inhibiting the cell cycle which could explain the low 
levels  of  proliferation  exhibited  by  budding  cells  [67, 
80]. Although it has been speculated that this change in 
intra-cellular localization within tumor buds may be due 
to promoter methylation of CDKN2A, the role of p16 
in  tumor  budding  in  both  MSS  and  MSI-H  colorectal 
cancers needs further clarification. In addition, it remains 
interesting that CIMP-H colorectal cancers, namely those 
with the lowest predicted amounts of tumor budding seem 
to be most responsive to chemotherapy [81]. 
cLINIcAL UsE OF tUMOr bUDDNIG
Prognostic and predictive impact of tumor 
budding
Tumor budding at the invasive front has been 
recognized as an adverse parameter and an “additional” 
prognostic factor by the International Union against 
Cancer  (UICC)  [16,  82].  High-grade  tumor  budding, 
irrespective  of  the  definition,  has  been  consistently 
linked to lymph node metastasis [3-8], distant metastasis 
[9],  local  recurrence  [10-15]  and  correlates  with  the 
distance of tumor invasion beyond the outer border of the 
muscularis propria [83]. Tumor budding is proposed as 
a useful indicator of isolated tumor cells in lymph nodes 
in  patients  with  node-negative  colorectal  cancers  [84] 
and could indicate additional laparotomy in patients with 
locally excised T1 tumors [85, 86]. 
The prognostic and independent effect of tumor 
budding on outcome has been investigated by several 
study  groups.  High-grade  tumor  budding  has  an 
independent adverse effect on both overall and disease-
free  survival  time  [23,  84,  87-92]  particularly  in  the 
presence of cytoplasmic podia [59] and may serve as an 
additional histopathological parameter to identify stage I 
or II patients at risk of disease recurrence after curative 
surgery [93-96]. Even among patients with node-positive 
or stage III disease, tumor budding has been shown to 
improve the risk stratification of patients [4, 97]. However, 
contradictory findings have been recently reported by Sy 
and colleagues who found an association of tumor budding 
with worse outcome in univariate but not multivariate 
analysis in this subset of patients [98]. Tumor budding 
may also be a predictive factor in metastatic colorectal 
cancer  patients  treated  with  anti-EGFR  therapies  [99]. 
In a retrospective cohort of treated metastatic colorectal 
cancer patients, high-grade tumor budding could predict 
non-response to therapy and in combination with KRAS 
mutational  status,  predicted  response  in  80%  of  cases. 
The predictive value of tumor budding to targeted therapy 
requires further investigation.  
In 1989, Morodomi and colleagues published what 
appears to be the only work evaluating the presence of 
tumor budding within the tumor centre from pre-operative 
biopsy specimens [100]. Not only did this type of tumor 
budding correlate highly with budding at the invasive 
front, but a clear association between increased numbers 
of tumor buds in the pre-operative biopsy specimen and 
lymphatic and lymph node positivity was observed. 
Further studies are warranted to investigate the potential 
of this “intra-tumoral” type of budding as a prognostic or 
predictive factor in the pre-treatment clinical management 
of colorectal cancer patients.
Scoring systems
Despite the clear associations of tumor budding 
with worse clinical outcome and more aggressive tumor 
parameters, tumor budding has yet to be implemented into 
daily diagnostic routine. The main reason for this is the 
absence  of  standardized  scoring  systems  and  sufficient 
evidence  of  inter-observer  reproducibility  for  selected 
evaluation methods. 
Two different types of scoring systems have been 
proposed: subjective and more quantitative/objective. In 
1993, Hase and colleagues presented a system based on Oncotarget 2010; 1:  651 - 661 657 www.impactjournals.com/oncotarget
the predominant pattern of tumor budding using a 2-tier 
method (none or minimal versus moderate or severe) 
[87]. Nakamura and colleagues, using a similar system, 
described tumor budding along the entire invasive margin 
using a 4-tier method (none, mild <1/3, moderate 1/3-2/3 
and severe >2/3) [9, 95]. More quantitative scoring systems 
have been reported. The group of Ueno and co-workers 
proposed 2 methods by counting the number of buds within 
the field of most dense tumor budding: (1) using a 20x 
objective lens (area 0.785 mm2) and a cut-off of 5 tumor 
buds or (2) using a 25x objective lens (area 0.385 mm2) 
with a cut-off of 10 tumor buds. Inter-observer agreement 
for the latter was reported at kappa=0.84 [23. 101]. Wang 
and colleagues presented a technique whereby 5 randomly 
selected areas were evaluated, each given a score based on 
presence (at least one bud) or absence of tumor budding 
in each field (area 0.949 mm2) and document an inter-
observer agreement of kappa=0.75 [92]. The evaluation of 
tumor budding cells can be significantly hindered in cases 
of stromal inflammation or fibrosis at the invasive front. 
Pan-cytokeratin immunostains facilitate significantly the 
visualization of tumor buds and are highly recommended 
for their evaluation [2]. Prall and colleagues scored pan-
cytokeratin-stained tumor buds in a 0.785 mm2 field of 
vision  (250x).  Rather  than  using  an  arbitrary  cut-off 
score to classify a case as “budding-positive”, they used 
an established statistical cut-point determination method 
(receiver operating characteristic (ROC) curve analysis) 
to  identify  the  “optimal”  number  of  tumor  buds  to  be 
used as a threshold value [96]. Classifying tumors of ≥25 
buds/field as positive, they report a strong inter-observer 
agreement  with  kappa=  0.874. Also  using  ROC  curve 
analysis, our group has shown that with 15 buds/high-
power field, the percent concordance between observers 
was 88% (kappa=0.6) [99]. 
These  results  show  the  potential  for  high-level 
inter-observer  agreement.  However,  consensus  has  not 
been reached yet and international collaborative efforts 
to standardize scoring of tumor budding are crucial 
before this feature can be implemented as part of routine 
diagnostic pathology. 
cONcLUsION
Tumor budding is not a static, histological feature; it 
represents a snap-shot of a dynamic process undertaken by 
an aggressive tumor with the potential to disseminate and 
metastasize. Tumor budding is worth to be therapeutically 
targeted;  the  overwhelming  and  consistent  evidence 
demonstrating that tumor budding is linked to unfavorable 
tumor-related  features,  aggressive  behavior  and  worse 
overall and disease-free survival time suggests that tumor 
budding should be considered an “essential” prognostic 
factor  along-side  pT,  pN,  pM,  lymphatic  and  vascular 
invasion [16]. As seen in breast and prostate cancers 
with the BRE and Gleason scores, respectively, tumor 
budding has the potential to be a basis for a supplementary 
prognostic scoring system in colorectal cancer once its 
evaluation has been standardized. The molecular and 
genetic events triggering a tumor budding phenotype, 
the changes occurring within tumor budding cells, their 
interaction  with  stromal  cells  and  the  identification  of 
more or less aggressive tumor budding profiles remain 
open areas of investigation. Understanding the interactions 
between tumor buds and the immune response may be 
key toward the development of future immunotherapy 
targeting the destruction of tumor budding cells.
cONFLIct OF INtErEst stAtEMENt
The authors have no conflicts of interest.
rEFErENcEs
1.   Kalluri  R,  Weinberg  RA.  The  basics  of  epithelial-
mesenchymal transition. J Clin Invest 2009;119:1420-8.
2.  Prall F. Tumour budding in colorectal carcinoma. 
Histopathology 2007;50:151-62.
3.   Hase  K,  Shatney  CH,  Mochizuki  H,  Johnson  DL, 
Tamakuma S, Vierra M, Trollope M. Long-term results 
of  curative  resection  of  “minimally  invasive”  colorectal 
cancer. Dis Colon Rectum 1995;38:19-26.
4.  Okuyama  T,  Oya  M,  Ishikawa  H.  Budding  as  a  useful 
prognostic marker in pT3 well- or moderately-differentiated 
rectal adenocarcinoma. J Surg Oncol 2003;83:42-7.
5.  Sohn DK, Chang HJ, Park JW, Choi DH, Han KS, Hong 
CW, Jung KH, Kim DY, Lim SB, Choi HS, Jeong SY. 
Histopathological risk factors for lymph node metastasis in 
submucosal invasive colorectal carcinoma of pedunculated 
or semipedunculated type. J Clin Pathol 2007;60:912-5.
6.  Tateishi  Y,  Nakanishi  Y,  Taniguchi  H,  Shimoda  T, 
Umemura S. Pathological prognostic factors predicting 
lymph node metastasis in submucosal invasive (T1) 
colorectal carcinoma. Mod Pathol;23:1068-72.
7.  Wang HS, Liang WY, Lin TC, Chen WS, Jiang JK, Yang 
SH, Chang SC, Lin JK. Curative resection of T1 colorectal 
carcinoma: risk of lymph node metastasis and long-term 
prognosis. Dis Colon Rectum 2005;48:1182-92.
8.  Yasuda K, Inomata M, Shiromizu A, Shiraishi N, Higashi 
H, Kitano S. Risk factors for occult lymph node metastasis 
of colorectal cancer invading the submucosa and indications 
for endoscopic mucosal resection. Dis Colon Rectum 
2007;50:1370-6.
9.  Nakamura  T,  Mitomi  H,  Kikuchi  S,  Ohtani  Y,  Sato  K. 
Evaluation of the usefulness of tumor budding on the 
prediction of metastasis to the lung and liver after curative 
excision of colorectal cancer. Hepatogastroenterology 
2005;52:1432-5.
10.  Compton  CC.  Pathologic  prognostic  factors  in  the 
recurrence of rectal cancer. Clin Colorectal Cancer Oncotarget 2010; 1:  651 - 661 658 www.impactjournals.com/oncotarget
2002;2:149-60.
11. Losi L, Ponti G, Gregorio CD, Marino M, Rossi 
G, Pedroni M, Benatti P, Roncucci L, de Leon MP. 
Prognostic  significance  of  histological  features  and 
biological parameters in stage I (pT1 and pT2) colorectal 
adenocarcinoma. Pathol Res Pract 2006;202:663-70.
12.  Masaki T, Matsuoka H, Sugiyama M, Abe N, Izumisato Y, 
Sakamoto A, Atomi Y. Laminin-5 gamma2 chain expression 
as a possible determinant of tumor aggressiveness in T1 
colorectal carcinomas. Dig Dis Sci 2003;48:272-8.
13.  Okuyama T, Oya M, Yamaguchi M. Budding (sprouting) 
as a useful prognostic marker in colorectal mucinous 
carcinoma. Jpn J Clin Oncol 2002;32:412-6.
14.  Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. 
Tumor budding at the invasive margin can predict patients 
at high risk of recurrence after curative surgery for stage II, 
T3 colon cancer. Dis Colon Rectum 2003;46:1054-9.
15. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, 
Fujimoto H, Hase K. Predictors of extrahepatic recurrence 
after resection of colorectal liver metastases. Br J Surg 
2004;91:327-33.
16.  Compton C. Prognostic factors in cancer, 3rd ed.ed.: Wiley-
Liss, 2006.
17.  Brabletz  T,  Jung  A,  Spaderna  S,  Hlubek  F,  Kirchner 
T.  Opinion:  migrating  cancer  stem  cells  -  an  integrated 
concept of malignant tumour progression. Nat Rev Cancer 
2005;5:744-9.
18.  Kalluri R. EMT: when epithelial cells decide to become 
mesenchymal-like cells. J Clin Invest 2009;119:1417-9.
19.  Moreno-Bueno  G,  Cubillo  E,  Sarrio  D,  Peinado  H, 
Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra 
A,  Portillo  F,  Palacios  J,  Cano  A.  Genetic  profiling  of 
epithelial cells expressing E-cadherin repressors reveals a 
distinct role for Snail, Slug, and E47 factors in epithelial-
mesenchymal transition. Cancer Res 2006;66:9543-56.
20.  Moreno-Bueno  G,  Peinado  H,  Molina  P,  Olmeda  D, 
Cubillo E, Santos V, Palacios J, Portillo F, Cano A. The 
morphological and molecular features of the epithelial-to-
mesenchymal transition. Nat Protoc 2009;4:1591-613.
21.  Brabletz  T,  Hlubek  F,  Spaderna  S,  Schmalhofer  O, 
Hiendlmeyer E, Jung A, Kirchner T. Invasion and 
metastasis  in  colorectal  cancer:  epithelial-mesenchymal 
transition,  mesenchymal-epithelial  transition,  stem  cells 
and beta-catenin. Cells Tissues Organs 2005;179:56-65.
22.  Guarino M, Rubino B, Ballabio G. The role of epithelial-
mesenchymal transition in cancer pathology. Pathology 
2007;39:305-18.
23.  Ueno  H,  Murphy  J,  Jass  JR,  Mochizuki  H,  Talbot  IC. 
Tumour ‘budding’ as an index to estimate the potential 
of aggressiveness in rectal cancer. Histopathology 
2002;40:127-32.
24.  Shinto E, Mochizuki H, Ueno H, Matsubara O, Jass JR. A 
novel classification of tumour budding in colorectal cancer 
based  on  the  presence  of  cytoplasmic  pseudo-fragments 
around budding foci. Histopathology 2005;47:25-31.
25.  Jass J. Tumor budding in colorectal cancer, Chapter 5ed. 
New York: Nova Science Publishers, 2006.
26.  Jass  JR,  Atkin  WS,  Cuzick  J,  Bussey  HJ,  Morson  BC, 
Northover  JM,  Todd  IP.  The  grading  of  rectal  cancer: 
historical perspectives and a multivariate analysis of 447 
cases. Histopathology 1986;10:437-59.
27.  Jass  JR.  Lymphocytic  infiltration  and  survival  in  rectal 
cancer. J Clin Pathol 1986;39:585-9.
28.  Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-
Schughart  LA,  Knuechel  R,  Kirchner  T.  Variable  beta-
catenin expression in colorectal cancers indicates tumor 
progression driven by the tumor environment. Proc Natl 
Acad Sci U S A 2001;98:10356-61.
29.  Larriba  MJ,  Casado-Vela  J,  Pendas-Franco  N,  Pena  R, 
Garcia de Herreros A, Berciano MT, Lafarga M, Casal 
JI,  Munoz  A.  Novel  snail1  target  proteins  in  human 
colon  cancer  identified  by  proteomic  analysis.  PLoS 
One;5:e10221.
30.  Roger L, Jullien L, Gire V, Roux P. Gain of oncogenic 
function of p53 mutants regulates E-cadherin expression 
uncoupled from cell invasion in colon cancer cells. J Cell 
Sci;123:1295-305.
31.  Sanchez-Tillo  E,  Lazaro  A,  Torrent  R,  Cuatrecasas  M, 
Vaquero EC, Castells A, Engel P, Postigo A. ZEB1 
represses E-cadherin and induces an EMT by recruiting 
the  SWI/SNF  chromatin-remodeling  protein  BRG1. 
Oncogene;29:3490-500.
32.  Brabletz S, Schmalhofer O, Brabletz T. Gastrointestinal stem 
cells in development and cancer. J Pathol 2009;217:307-17.
33.  Kim S, Kang HY, Nam EH, Choi MS, Zhao XF, Hong 
CS,  Lee  JW,  Lee  JH,  Park  YK.  TMPRSS4  induces 
invasion  and  epithelial-mesenchymal  transition  through 
upregulation of integrin alpha5 and its signaling pathways. 
Carcinogenesis;31:597-606.
34.  Pelaez  IM,  Kalogeropoulou  M,  Ferraro  A,  Voulgari  A, 
Pankotai  T,  Boros  I,  Pintzas  A.  Oncogenic  RAS  alters 
the global and gene-specific histone modification pattern 
during  epithelial-mesenchymal  transition  in  colorectal 
carcinoma cells. Int J Biochem Cell Biol;42:911-20.
35.  Bates  RC,  Pursell  BM,  Mercurio  AM.  Epithelial-
mesenchymal transition and colorectal cancer: gaining 
insights into tumor progression using LIM 1863 cells. Cells 
Tissues Organs 2007;185:29-39.
36.  Katoh M, Katoh M. Cross-talk of WNT and FGF signaling 
pathways at GSK3beta to regulate beta-catenin and SNAIL 
signaling cascades. Cancer Biol Ther 2006;5:1059-64.
37.  Ceccarelli C, Piazzi G, Paterini P, Pantaleo MA, Taffurelli 
M, Santini D, Martinelli GN, Biasco G. Concurrent EGFr 
and  Cox-2  expression  in  colorectal  cancer:  proliferation 
impact and tumour spreading. Ann Oncol 2005;16 Suppl 
4:iv74-79.
38.  Guzinska-Ustymowicz K, Kemona A. Transforming growth 
factor beta can be a parameter of aggressiveness of pT1 Oncotarget 2010; 1:  651 - 661 659 www.impactjournals.com/oncotarget
colorectal cancer. World J Gastroenterol 2005;11:1193-5.
39.  Ljuslinder I, Melin B, Henriksson ML, Oberg A, Palmqvist 
R. Increased epidermal growth factor receptor expression 
at the invasive margin is a negative prognostic factor in 
colorectal cancer. Int J Cancer 2010.
40.  Markl B, Renk I, Oruzio DV, Jahnig H, Schenkirsch G, 
Scholer  C,  Ehret  W,  Arnholdt  HM,  Anthuber  M,  Spatz 
H. Tumour budding, uPA and PAI-1 are associated with 
aggressive  behaviour  in  colon  cancer.  J  Surg  Oncol 
2010;102:235-41.
41.  Masaki T, Sugiyama M, Matsuoka H, Abe N, Izumisato 
Y, Sakamoto A, Atomi Y. Coexpression of matrilysin 
and  laminin-5  gamma2  chain  may  contribute  to  tumor 
cell migration in colorectal carcinomas. Dig Dis Sci 
2003;48:1262-7.
42.  Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, 
Zlobec I. Urokinase-type plasminogen activator is a marker 
of aggressive phenotype and an independent prognostic 
factor in mismatch repair-proficient colorectal cancer. Hum 
Pathol 2009.
43.  Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason 
K. Laminin-5 is a marker of invading cancer cells in some 
human carcinomas and is coexpressed with the receptor for 
urokinase plasminogen activator in budding cancer cells in 
colon adenocarcinomas. Cancer Res 1995;55:4132-9.
44.  Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki 
T, Saitoh Y, Kohgo Y. Reduced expression of syndecan-1 
affects metastatic potential and clinical outcome in patients 
with colorectal cancer. Jpn J Cancer Res 2001;92:1074-81.
45.  Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano 
L, Jass JR. Role of the mitogen-activated protein kinase 
and phosphoinositide 3-kinase/AKT pathways downstream 
molecules,  phosphorylated  extracellular  signal-
regulated kinase, and phosphorylated AKT in colorectal 
cancer-a  tissue  microarray-based  approach.  Hum  Pathol 
2006;37:1022-31.
46.  Zlobec I, Lugli A, Baker K, Roth S, Minoo P, Hayashi S, 
Terracciano L, Jass JR. Role of APAF-1, E-cadherin and 
peritumoral lymphocytic infiltration in tumour budding in 
colorectal cancer. J Pathol 2007;212:260-8.
47.  Karamitopoulou E, Lugli A, Panayiotides I, Karakitsos P, 
Peros G, Rallis G, Patsouris ES, Terracciano L, Zlobec I. 
Systematic assessment of protein phenotypes characterizing 
high-grade tumour budding in mismatch repair-proficient 
colorectal cancer. Histopathology 2010;57:233-43.
48.  Coppola D, Hyacinthe M, Fu L, Cantor AB, Karl R, Marcet 
J, Cooper DL, Nicosia SV, Cooper HS. CD44V6 expression 
in human colorectal carcinoma. Hum Pathol 1998;29:627-
35.
49.  Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken 
JH, Nagtegaal ID. Loss of membranous Ep-CAM in budding 
colorectal carcinoma cells. Mod Pathol 2007;20:221-32.
50.  Nanashima  A,  Yamaguchi  H,  Sawai  T,  Yasutake  T, 
Tsuji T, Jibiki M, Yamaguchi E, Nakagoe T, Ayabe H. 
Expression of adhesion molecules in hepatic metastases of 
colorectal carcinoma: relationship to primary tumours and 
prognosis after hepatic resection. J Gastroenterol Hepatol 
1999;14:1004-9.
51. Zlobec I, Gunthert U, Tornillo L, Iezzi G, Baumhoer 
D, Terracciano L, Lugli A. Systematic assessment 
of  the  prognostic  impact  of  membranous  CD44v6 
protein expression in colorectal cancer. Histopathology 
2009;55:564-75.
52.  Ponta H, Sherman L, Herrlich PA. CD44: from adhesion 
molecules to signalling regulators. Nat Rev Mol Cell Biol 
2003;4:33-45.
53.  Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. 
Epithelial cell adhesion molecule: more than a carcinoma 
marker and adhesion molecule. Am J Pathol 2007;171:386-
95.
54.  Vessey CJ, Wilding J, Folarin N, Hirano S, Takeichi M, 
Soutter  P,  Stamp  GW,  Pignatelli  M.  Altered  expression 
and  function  of  E-cadherin  in  cervical  intraepithelial 
neoplasia and invasive squamous cell carcinoma. J Pathol 
1995;176:151-9.
55.  Brabletz T. Tumor Budding in Colorectal Cancer; Chapter 
4ed. New York: Nova Science Publishers, Inc., 2006.
56.  Horkko TT, Klintrup K, Makinen JM, Napankangas JB, 
Tuominen HJ, Makela J, Karttunen TJ, Makinen MJ. 
Budding invasive margin and prognosis in colorectal 
cancer--no direct association with beta-catenin expression. 
Eur J Cancer 2006;42:964-71.
57.  Guzinska-Ustymowicz  K.  MMP-9  and  cathepsin  B 
expression in tumor budding as an indicator of a more 
aggressive phenotype of colorectal cancer (CRC). 
Anticancer Res 2006;26:1589-94.
58.  Masaki  T,  Goto  A,  Sugiyama  M,  Matsuoka  H,  Abe  N, 
Sakamoto  A,  Atomi  Y.  Possible  contribution  of  CD44 
variant  6  and  nuclear  beta-catenin  expression  to  the 
formation of budding tumor cells in patients with T1 
colorectal carcinoma. Cancer 2001;92:2539-46.
59.  Shinto  E,  Jass  JR,  Tsuda  H,  Sato  T,  Ueno  H,  Hase  K, 
Mochizuki  H,  Matsubara  O.  Differential  prognostic 
significance of morphologic invasive markers in colorectal 
cancer: tumor budding and cytoplasmic podia. Dis Colon 
Rectum 2006;49:1422-30.
60.  Akishima-Fukasawa  Y,  Nakanishi  Y,  Ino  Y,  Moriya  Y, 
Kanai Y, Hirohashi S. Prognostic significance of CXCL12 
expression in patients with colorectal carcinoma. Am J Clin 
Pathol 2009;132:202-10; quiz 307.
61.  Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ, Zhang 
X,  Pan  ZZ,  Wan  DS,  Zeng  YX,  Zhu  XF,  Zhang  XS. 
Higher percentage of CD133+ cells is associated with poor 
prognosis in colon carcinoma patients with stage IIIB. J 
Transl Med 2009;7:56.
62.  Portyanko A, Kovalev P, Gorgun J, Cherstvoy E. beta(III)-
tubulin at the invasive margin of colorectal cancer: possible 
link to invasion. Virchows Arch 2009;454:541-8.Oncotarget 2010; 1:  651 - 661 660 www.impactjournals.com/oncotarget
63.  Toyoda A, Kawana H, Azuhata K, Yu J, Omata A, Kishi 
H, Higashi M, Harigaya K. Aberrant expression of human 
ortholog of mammalian enabled (hMena) in human 
colorectal carcinomas: implications for its role in tumor 
progression. Int J Oncol 2009;34:53-60.
64.  Hostettler L, Zlobec I, Terracciano L, Lugli A. ABCG5-
positivity in tumor buds is an indicator of poor prognosis 
in  node-negative  colorectal  cancer  patients.  World  J 
Gastroenterol 2010;16:732-9.
65.  Jung  A,  Schrauder  M,  Oswald  U,  Knoll  C,  Sellberg  P, 
Palmqvist R, Niedobitek G, Brabletz T, Kirchner T. The 
invasion front of human colorectal adenocarcinomas 
shows co-localization of nuclear beta-catenin, cyclin D1, 
and p16INK4A and is a region of low proliferation. Am J 
Pathol 2001;159:1613-7.
66.  Rubio CA. Arrest of cell proliferation in budding tumor 
cells ahead of the invading edge of colonic carcinomas. A 
preliminary report. Anticancer Res 2008;28:2417-20.
67.  Jass  JR,  Barker  M,  Fraser  L,  Walsh  MD,  Whitehall 
VL, Gabrielli B, Young J, Leggett BA. APC mutation 
and tumour budding in colorectal cancer. J Clin Pathol 
2003;56:69-73.
68.  Zlobec I, Lugli A. Invasive front of colorectal cancer: 
dynamic  interface  of  pro-/anti-tumor  factors.  World  J 
Gastroenterol 2009;15:5898-906.
69.  Popat S, Hubner R, Houlston RS. Systematic review of 
microsatellite instability and colorectal cancer prognosis. J 
Clin Oncol 2005;23:609-18.
70.  Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, 
Searle J, Radford-Smith G, Young J, Leggett B. Morphology 
of sporadic colorectal cancer with DNA replication errors. 
Gut 1998;42:673-9.
71.  Jenkins MA, Hayashi S, O’Shea AM, Burgart LJ, Smyrk 
TC,  Shimizu  D,  Waring  PM,  Ruszkiewicz  AR,  Pollett 
AF, Redston M, Barker MA, Baron JA, et al. Pathology 
features in Bethesda guidelines predict colorectal cancer 
microsatellite  instability:  a  population-based  study. 
Gastroenterology 2007;133:48-56.
72.  Zlobec  I,  Minoo  P,  Terracciano  L,  Baker  K,  Lugli  A. 
Characterization of the immunological microenvironment 
of tumour buds and its impact on prognosis in mismatch 
repair-proficient  and  –deficient  colorectal  cancers. 
Histopathology In press.
73.  Baker  K,  Zlobec  I,  Tornillo  L,  Terracciano  L,  Jass  JR, 
Lugli  A.  Differential  significance  of  tumour  infiltrating 
lymphocytes  in  sporadic  mismatch  repair  deficient 
versus  proficient  colorectal  cancers:  a  potential  role  for 
dysregulation  of  the  transforming  growth  factor-beta 
pathway. Eur J Cancer 2007;43:624-31.
74.  Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, 
Berger D, Park DY, Iafrate AJ, Zukerberg LR, Chung 
DC. Epithelial to Mesenchymal Transition Is Impaired 
in  Colon  Cancer  Cells  With  Microsatellite  Instability. 
Gastroenterology 2009.
75.  Shima  K,  Nosho  K,  Baba  Y,  Cantor  M,  Meyerhardt 
JA,  Giovannucci  EL,  Fuchs  CS,  Ogino  S.  Prognostic 
significance of CDKN2A (p16) promoter methylation and 
loss of expression in 902 colorectal cancers: Cohort study 
and literature review. Int J Cancer 2010.
76.  Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, 
Ilyas  M,  Bodmer  WF,  Moyer  MP,  Riecken  EO,  Buhr 
HJ, Hanski C. Target genes of beta-catenin-T cell-factor/
lymphoid-enhancer-factor  signaling  in  human  colorectal 
carcinomas. Proc Natl Acad Sci U S A 1999;96:1603-8.
77.  Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin 
SB, Issa JP. CpG island methylator phenotype in colorectal 
cancer. Proc Natl Acad Sci U S A 1999;96:8681-6.
78.  Prall  F,  Ostwald  C,  Weirich  V,  Nizze  H.  p16(INK4a) 
promoter methylation and 9p21 allelic loss in colorectal 
carcinomas: relation with immunohistochemical 
p16(INK4a)  expression  and  with  tumor  budding.  Hum 
Pathol 2006;37:578-85.
79.  Schneider-Stock R, Boltze C, Peters B, Hopfner T, Meyer 
F, Lippert H, Roessner A. Differences in loss of p16INK4 
protein expression by promoter methylation between left- 
and right-sided primary colorectal carcinomas. Int J Oncol 
2003;23:1009-13.
80.  Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. 
Cyclin D2 activates Cdk2 in preference to Cdk4 in human 
breast epithelial cells. Oncogene 1997;14:1329-40.
81.  Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta 
B. CpG island methylator phenotype is an independent 
predictor of survival benefit from 5-fluorouracil in stage III 
colorectal cancer. Clin Cancer Res 2003;9:2898-903.
82.  Turner  RR,  Li  C,  Compton  CC.  Newer  pathologic 
assessment techniques for colorectal carcinoma. Clin 
Cancer Res 2007;13:6871s-6s.
83.  Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa 
K. The depth of tumor invasion beyond the outer border of 
the muscularis propria as a prognostic factor for T3 rectal/
rectosigmoid cancer. Anticancer Res 2008;28:1773-8.
84.  Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of 
tumor budding and its prognostic implications in invasive 
colon carcinoma. Dis Colon Rectum 2005;48:1597-602.
85.  Masaki T, Matsuoka H, Sugiyama M, Abe N, Sakamoto 
A, Atomi Y. Actual number of tumor budding as a new 
tool for the individualization of treatment of T1 colorectal 
carcinomas. J Gastroenterol Hepatol 2006;21:1115-21.
86.  Ueno H, Hashiguchi Y, Kajiwara Y, Shinto E, Shimazaki 
H, Kurihara H, Mochizuki H, Hase K. Proposed objective 
criteria for «grade 3» in early invasive colorectal cancer. 
Am J Clin Pathol;134:312-22.
87.  Hase  K,  Shatney  C,  Johnson  D,  Trollope  M,  Vierra  M. 
Prognostic  value  of  tumor  «budding»  in  patients  with 
colorectal cancer. Dis Colon Rectum 1993;36:627-35.
88.  Kanazawa H, Mitomi H, Nishiyama Y, Kishimoto I, Fukui 
N, Nakamura T, Watanabe M. Tumour budding at invasive 
margins and outcome in colorectal cancer. Colorectal Dis Oncotarget 2010; 1:  651 - 661 661 www.impactjournals.com/oncotarget
2008;10:41-7.
89.  Nilsson PJ, Rubio C, Lenander C, Auer G, Glimelius B. 
Tumour budding detected by laminin-5 {gamma}2-chain 
immunohistochemistry is of prognostic value in epidermoid 
anal cancer. Ann Oncol 2005;16:893-8.
90.  Ohtsuki K, Koyama F, Tamura T, Enomoto Y, Fujii H, 
Mukogawa  T,  Nakagawa  T,  Uchimoto  K,  Nakamura 
S,  Nonomura  A,  Nakajima  Y.  Prognostic  value  of 
immunohistochemical analysis of tumor budding in 
colorectal carcinoma. Anticancer Res 2008;28:1831-6.
91.  Ueno  H,  Price  AB,  Wilkinson  KH,  Jass  JR,  Mochizuki 
H, Talbot IC. A new prognostic staging system for rectal 
cancer. Ann Surg 2004;240:832-9.
92.  Wang LM, Kevans D, Mulcahy H, O›Sullivan J, Fennelly 
D, Hyland J, O›Donoghue D, Sheahan K. Tumor budding 
is a strong and reproducible prognostic marker in T3N0 
colorectal cancer. Am J Surg Pathol 2009;33:134-41.
93.  Masaki  T,  Matsuoka  H,  Sugiyama  M,  Abe  N,  Goto  A, 
Sakamoto A, Atomi Y. Matrilysin (MMP-7) as a significant 
determinant of malignant potential of early invasive 
colorectal carcinomas. Br J Cancer 2001;84:1317-21.
94.  Masaki T, Matsuoka H, Sugiyama M, Abe N, Sakamoto 
A, Watanabe T, Nagawa H, Atomi Y. Tumor budding and 
evidence-based treatment of T2 rectal carcinomas. J Surg 
Oncol 2005;92:59-63.
95.  Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe 
M. Tumor budding as an index to identify high-risk patients 
with stage II colon cancer. Dis Colon Rectum 2008;51:568-
72.
96.  Prall F, Nizze H, Barten M. Tumour budding as prognostic 
factor in stage I/II colorectal carcinoma. Histopathology 
2005;47:17-24.
97.  Choi HJ, Park KJ, Shin JS, Roh MS, Kwon HC, Lee HS. 
Tumor budding as a prognostic marker in stage-III rectal 
carcinoma. Int J Colorectal Dis 2007;22:863-8.
98.  Sy J, Fung CL, Dent OF, Chapuis PH, Bokey L, Chan 
C. Tumor budding and survival after potentially curative 
resection  of  node-positive  colon  cancer.  Dis  Colon 
Rectum;53:301-7.
99.  Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, 
Trezzi R, Dosso SD, Vlajnic T, Frattini M, Lugli A. Tumor 
budding  predicts  response  to  anti-EGFR  therapies  in 
metastatic colorectal cancer patients. World J Gastroenterol 
2010;16:4823-31.
100. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie 
K, Morimatsu M. An index for estimating the probability 
of lymph node metastasis in rectal cancers. Lymph node 
metastasis and the histopathology of actively invasive 
regions of cancer. Cancer 1989;63:539-43.
101. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida 
S, Hase K, Matsukuma S, Kanai T, Kurihara H, Ozawa K, 
Yoshimura K, Bekku S. Risk factors for an adverse outcome 
in early invasive colorectal carcinoma. Gastroenterology 
2004;127:385-94.